2018 Consensus of the French Society of Endocrinology: endocrine toxicities of cancer immunotherapies
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | 2018 Consensus of the French Society of Endocrinology: endocrine toxicities of cancer immunotherapies |
| Type de publication | Journal Article |
| Year of Publication | 2019 |
| Auteurs | Costinetti F, Borson-Chazot F, Aibarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Cao CDo, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, 2018 CSFE |
| Journal | CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION |
| Volume | 23 |
| Pagination | 31-36 |
| Date Published | MAR-APR |
| Type of Article | Article |
| ISSN | 2100-9619 |
| Mots-clés | adrenal insufficiency, diabetes, Hypophysitis, Immunotherapy, Thyroiditis |
| Résumé | Immunotherapy induced side effects: Are frequent, usually well-tolerated, and can lead to thyroid, pituitary, and less frequently adrenals and pancreas (fulminant diabetes) disease,. Do not contra-indicate immunotherapy, and rarely require high dose glucocorticoids; Need to be screened for, as there are acute manifestations, and replacement treatments can be given lifelong; Require a pre-immunotherapy evaluation; Require a careful follow-up at least during the first 6 months of immunotherapy. |